Outlook Therapeutics to Present at Major Investment Conference
ISELIN, N.J. — Outlook Therapeutics, Inc. (NASDAQ: OTLK), a biopharmaceutical company focused on innovative ophthalmic treatments, is preparing to present at the H.C. Wainwright 26th Annual Global Investment Conference in New York. This important event will take place from September 9 to 11, 2024, providing a valuable opportunity for companies to showcase their latest advancements and engage with investors.
Presentation Highlights
Russell Trenary, Outlook Therapeutics' President and CEO, will take the stage to highlight the company's progress, particularly its pioneering ophthalmic formulation of bevacizumab designed for the treatment of wet age-related macular degeneration (wet AMD). Known as LYTENAVA™ (bevacizumab gamma), this formulation is the first of its kind to receive regulatory approval in both the European Union and the United Kingdom, representing a significant milestone in retinal therapy.
Engagement Opportunities
Alongside the presentation, the management team will be available for one-on-one meetings with registered investors. This is a vital opportunity for stakeholders to engage directly with the company's leadership, allowing for in-depth discussions about Outlook Therapeutics' mission and its ongoing development of transformative therapies.
Webcast Availability
A video webcast of the presentation will be accessible for on-demand viewing starting September 9, 2024. This ensures that those unable to attend the live event can still access the insights shared. The session will be available on the company’s Events page and will remain archived for 90 days, allowing interested parties to catch up on the conference highlights.
About Outlook Therapeutics, Inc.
Outlook Therapeutics is committed to providing innovative solutions for retinal diseases like wet AMD through its investigational product, ONS-5010/LYTENAVA™. With its recent approval in the EU and UK, the company is preparing for a commercial launch anticipated in the first half of 2025. In the United States, this product is still undergoing evaluation, with plans to submit a Biologics License Application (BLA) contingent on the outcomes of ongoing studies. If successful, this could lead to the first approved ophthalmic formulation of bevacizumab for retinal use in the U.S.
Investor Inquiries:
Jenene Thomas
Chief Executive Officer
JTC Team, LLC
T: 833.475.8247
Email: OTLK@jtcir.com
Frequently Asked Questions
What is the purpose of the H.C. Wainwright conference?
The conference serves as a platform for companies like Outlook Therapeutics to showcase their latest developments and connect with potential investors.
What is LYTENAVA™?
LYTENAVA™ (bevacizumab gamma) is an ophthalmic formulation that has been approved for the treatment of wet AMD, marking a significant advancement in retinal therapies.
When will the presentation be available for viewing?
The presentation will be available for on-demand viewing starting September 9, 2024, and will be accessible for 90 days thereafter.
Who will be presenting at the conference?
Russell Trenary, the President and CEO of Outlook Therapeutics, will represent the company during the event.
What are the future plans for Outlook Therapeutics?
The company plans to launch LYTENAVA™ commercially in the EU and UK in the first half of 2025, while also evaluating its other investigational products in the U.S.
